Entropy and oligomerization in GPCRs

Evolutionary trace (ET) and entropy are two related methods for analyzing a multiple sequence alignment to determine functionally important residues in proteins. In this article, these methods have been enhanced with a view to reinvestigate the issue of GPCR dimerization and oligomerization. In particular, cluster analysis has replaced the subjective visual analysis element of the original ET method. Previous applications of the ET method predicted two dimerization interfaces on the external transmembrane lipid-facing region of GPCRs; these were discussed in terms of dimerization and linear oligomers. Removing the subjective element of the ET method gives rise to the prediction of functionally important residues on the external face of each transmembrane helix for a large number of class A GPCRs. These results are consistent with a growing body of experimental information that, taken over many receptor subtypes, has implicated each transmembrane helix in dimeric interactions. In this application, entropy gave superior results to those obtained from the ET method in that its use gives rise to higher z-scores and fewer instances of z-scores below 3.

[1]  Alfonso Valencia,et al.  Identification of amino acid residues crucial for chemokine receptor dimerization , 2004, Nature Immunology.

[2]  B. Borowsky,et al.  GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. , 1998, Nature.

[3]  L. Devi,et al.  Functional interactions between mu opioid and alpha 2A-adrenergic receptors. , 2003, Molecular pharmacology.

[4]  A. Helenius,et al.  Glycan-dependent and -independent Association of Vesicular Stomatitis Virus G Protein with Calnexin* , 1996, The Journal of Biological Chemistry.

[5]  Kenneth A. Jones,et al.  GABAB receptors function as a heteromeric assembly of the subunits GABABR1 and GABABR2 , 1998, Nature.

[6]  Alan Wise,et al.  Heterodimerization is required for the formation of a functional GABAB receptor , 1998, Nature.

[7]  J. W. Wells,et al.  Oligomeric potential of the M2 muscarinic cholinergic receptor , 2004, Journal of neurochemistry.

[8]  Georgios G. Gkoutos,et al.  Lipid-facing correlated mutations and dimerization in G-protein coupled receptors. , 2001, Protein engineering.

[9]  F E Cohen,et al.  Evolutionarily conserved Galphabetagamma binding surfaces support a model of the G protein-receptor complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Lakshmi A Devi,et al.  A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Valencia,et al.  Correlated mutations contain information about protein-protein interaction. , 1997, Journal of molecular biology.

[12]  C. Reynolds,et al.  Simulations on dimeric peptides: evidence for domain swapping in G-protein-coupled receptors? , 1997, Biochemical Society transactions.

[13]  G M Shepherd,et al.  Potential ligand-binding residues in rat olfactory receptors identified by correlated mutation analysis. , 1995, Receptors & channels.

[14]  J. W. Wells,et al.  Cooperativity Manifest in the Binding Properties of Purified Cardiac Muscarinic Receptors (*) , 1995, The Journal of Biological Chemistry.

[15]  Manfred Burghammer,et al.  Structure of bovine rhodopsin in a trigonal crystal form. , 2003, Journal of molecular biology.

[16]  Krzysztof Palczewski,et al.  Organization of the G Protein-coupled Receptors Rhodopsin and Opsin in Native Membranes* , 2003, Journal of Biological Chemistry.

[17]  Gert Vriend,et al.  GPCRDB information system for G protein-coupled receptors , 2003, Nucleic Acids Res..

[18]  Paul D. Scott,et al.  Dimerization of G-protein-coupled receptors. , 2001 .

[19]  Marta Filizola,et al.  Structural models for dimerization of G-protein coupled receptors: the opioid receptor homodimers. , 2002, Biopolymers.

[20]  J. Wess,et al.  Identification and Molecular Characterization of m3 Muscarinic Receptor Dimers* , 1999, The Journal of Biological Chemistry.

[21]  A. Dolphin,et al.  The G protein-linked receptor facts book Edited by S. Watson and S. Arkinstall. Academic Press, 427 pp. Price £19.50 , 1994, Neuroscience.

[22]  P. Fossier,et al.  Monitoring of Ligand-independent Dimerization and Ligand-induced Conformational Changes of Melatonin Receptors in Living Cells by Bioluminescence Resonance Energy Transfer* 210 , 2002, The Journal of Biological Chemistry.

[23]  H. Lother,et al.  Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness , 2001, Nature Medicine.

[24]  H. Vogel,et al.  Oligomerization of the alpha 1a- and alpha 1b-adrenergic receptor subtypes. Potential implications in receptor internalization. , 2003, The Journal of biological chemistry.

[25]  C. Higgs,et al.  Evidence for dimerization in the beta(2)-adrenergic receptor from the evolutionary trace method , 1999 .

[26]  C. Romano,et al.  Metabotropic Glutamate Receptor 5 Is a Disulfide-linked Dimer* , 1996, The Journal of Biological Chemistry.

[27]  Jean-François Mercier,et al.  Quantitative Assessment of β1- and β2-Adrenergic Receptor Homo- and Heterodimerization by Bioluminescence Resonance Energy Transfer* , 2002, The Journal of Biological Chemistry.

[28]  C Higgs,et al.  Domain swapping in G-protein coupled receptor dimers. , 1998, Protein engineering.

[29]  J. W. Wells,et al.  Monomers and oligomers of the M2 muscarinic cholinergic receptor purified from Sf9 cells. , 2003, Biochemistry.

[30]  Christopher A Reynolds,et al.  Dimerization and Domain Swapping in G-Protein-Coupled Receptors: A Computational Study , 2000, Neuropsychopharmacology.

[31]  David J. Daniels,et al.  A Bivalent Ligand (KDN-21) Reveals Spinal δ and κ Opioid Receptors Are Organized as Heterodimers That Give Rise to δ1 and κ2 Phenotypes. Selective Targeting of δ−κ Heterodimers , 2004 .

[32]  Jean-François Mercier,et al.  Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. , 2002, The Journal of biological chemistry.

[33]  J. W. Wells,et al.  Nature of the oligomers formed by muscarinic m2 acetylcholine receptors in Sf9 cells. , 2001, European journal of pharmacology.

[34]  Michel Bouvier,et al.  A Peptide Derived from a β2-Adrenergic Receptor Transmembrane Domain Inhibits Both Receptor Dimerization and Activation* , 1996, The Journal of Biological Chemistry.

[35]  E. Brown,et al.  Dimerization of the Extracellular Calcium-sensing Receptor (CaR) on the Cell Surface of CaR-transfected HEK293 Cells* , 1998, The Journal of Biological Chemistry.

[36]  Orkun S. Soyer,et al.  Dimerization in aminergic G-protein-coupled receptors: application of a hidden-site class model of evolution. , 2003, Biochemistry.

[37]  G Vriend,et al.  WHAT IF: a molecular modeling and drug design program. , 1990, Journal of molecular graphics.

[38]  J. W. Wells,et al.  Cardiac muscarinic receptors. Relationship between the G protein and multiple states of affinity. , 1997, Biochemistry.

[39]  C. Reynolds,et al.  A new approach to docking in the beta 2-adrenergic receptor that exploits the domain structure of G-protein-coupled receptors. , 1997, Journal of medicinal chemistry.

[40]  J. W. Wells,et al.  Cooperativity and oligomeric status of cardiac muscarinic cholinergic receptors. , 2002, Biochemistry.

[41]  Michel Bouvier,et al.  Constitutive Agonist-independent CCR5 Oligomerization and Antibody-mediated Clustering Occurring at Physiological Levels of Receptors* 210 , 2002, The Journal of Biological Chemistry.

[42]  Horst Vogel,et al.  Oligomerization of the α1a- and α1b-Adrenergic Receptor Subtypes , 2003, Journal of Biological Chemistry.

[43]  Marta Filizola,et al.  Prediction of heterodimerization interfaces of G-protein coupled receptors with a new subtractive correlated mutation method. , 2002, Protein engineering.

[44]  B. O'dowd,et al.  D2 dopamine receptor homodimerization is mediated by multiple sites of interaction, including an intermolecular interaction involving transmembrane domain 4. , 2003, Biochemistry.

[45]  Graeme Milligan,et al.  Domain Swapping in the Human Histamine H1 Receptor , 2004, Journal of Pharmacology and Experimental Therapeutics.

[46]  P. Strange,et al.  Dopamine D2 Receptor Dimer Formation , 2001, The Journal of Biological Chemistry.

[47]  J. Wess,et al.  Coexpression studies with mutant muscarinic/adrenergic receptors provide evidence for intermolecular "cross-talk" between G-protein-linked receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. W. Wells,et al.  Cardiac muscarinic receptors. Cooperativity as the basis for multiple states of affinity. , 1997, Biochemistry.

[49]  B. Mouillac,et al.  Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. , 2003, Molecular endocrinology.

[50]  Graeme Milligan,et al.  Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. , 2002, The Biochemical journal.

[51]  Lakshmi A. Devi,et al.  A role for heterodimerization of μ and δ opiate receptors in enhancing morphine analgesia , 2004 .

[52]  C. Sander,et al.  Correlated mutations and residue contacts in proteins , 1994, Proteins.

[53]  Lei Shi,et al.  The Fourth Transmembrane Segment Forms the Interface of the Dopamine D2 Receptor Homodimer* , 2003, The Journal of Biological Chemistry.

[54]  David J. Daniels,et al.  A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers. , 2004, Journal of medicinal chemistry.

[55]  R. Shigemoto,et al.  GABAB-receptor subtypes assemble into functional heteromeric complexes , 1998, Nature.